UFH is the Most Used Anticoagulant in Hemodialysis, Decreasing the Risk of Clot Formation in the Circuit.
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to verify the clinical non-inferiority of the pharmacodynamic
effects and the safety of use of the drug Heptar® manufactured by Eurofarma Laboratory,
compared to the drug Liquemine®, manufactured by by Roche Laboratory in patients with renal
failure undergoing hemodialysis treatment